Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
收藏数据链接：
官方服务：
资源简介：
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
应用场景：
创建时间：
2022-12-21
相关数据集
Dynamic trend of neutralizing antibody GMTs (95%CI) for EV71 FCP-As.
Female BALB/c mice (4–6 weeks old) were i.p. inoculated with three EV71 FCP-As (V1, V2, and V3) containing 200 U antigen. The sera were isolated and tested at 7, 14, 21, 28, 56 and 84 d post-inoculati
NIAID Data Ecosystem100
Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults
Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults
NCATS Open Data2022-11-08 更新00
Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC
Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC
NCATS Open Data2022-02-18 更新00
Dataset from Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy childre
NIAID Data Ecosystem10
Safety and immunogenicity of SW-BIC-213, a modified COVID-19 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18 years and above: a Phase 1/2 trial
Safety and immunogenicity of SW-BIC-213, a modified COVID-19 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18 years and above: a Phase 1/2 trial
NCATS Open Data2023-10-12 更新00
